Tenax Therapeutics, INC

Tenax Therapeutics announced its second quarter 2026 financial results, highlighting a strong cash position and providing an update on its pivotal Phase 3 LEVEL clinical trial, with topline data anticipated in August 2026.

Tenax Therapeutics will present results from its Phase 3 LEVEL clinical trial at the European Society of Cardiology (ESC) Congress 2026, with topline data expected in August 2026.

Tenax Therapeutics, Inc. has entered into a definitive Supply Agreement with Orion Corporation for its orally administered levosimendan product, alongside a Sixth Amendment to their existing License Agreement.

Tenax Therapeutics, Inc. has amended employment agreements for key executives, establishing severance and change-in-control benefits.

Tenax Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Tenax Therapeutics reported Q1 2026 financial results, highlighting progress in its Phase 3 LEVEL study for TNX-103 and strengthening its leadership team.

Tenax Therapeutics reports increased R&D spending for Phase 3 trials of levosimendan, with cash reserves projected to fund operations through Q2 2028.

Tenax Therapeutics reports a significant increase in R&D expenses for Q1 2026, driven by ongoing Phase 3 trials for levosimendan, while extending its cash runway into early 2028.

Tenax Therapeutics reported a significant increase in net loss for Q3 and the nine months ended September 30, 2025, driven by expanded clinical trial activities and higher operating expenses, while maintaining sufficient cash for operations through 2027.

Tenax Therapeutics reported increased cash reserves and accelerated R&D spending to advance its Phase 3 levosimendan program for pulmonary hypertension, despite widening net losses.

Tenax Therapeutics reports increased operating expenses and net loss for Q1 2025, offset by a strong cash position following recent equity offerings.

Tenax Therapeutics reports a significant increase in cash and cash equivalents to $98.3 million following a $99.7 million private placement, enabling the company to fund operations through 2027.

Tenax Therapeutics' 10-K filing reveals a significant increase in research and development expenses as the company progresses with its Phase 3 clinical trial for oral levosimendan.

Tenax Therapeutics' 10-K filing details its capital structure, recent reverse stock splits, and strategic focus on advancing its levosimendan program.

Christopher Thomas Giordano, CEO and a Director of Tenax Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

Tenax Therapeutics CFO Thomas R. Staab II was granted 10,000 restricted shares and 450,000 stock options.

Tenax Therapeutics' Interim CFO, Thomas McGauley, was granted 50,000 stock options with a future vesting schedule.

TENAX Therapeutics Director Michael H. Davidson filed a Form 4 detailing his beneficial ownership of common stock and various derivative securities, including new stock options and warrants.

TENAX THERAPEUTICS CEO Christopher Thomas Giordano filed a Form 4 detailing his beneficial ownership of common stock and various stock options.

TENAX THERAPEUTICS, INC. Chief Medical Officer Stuart Rich reported the acquisition of 250,000 new stock options with an exercise price of $13.30, alongside other option grants and existing holdings.

Tenax Therapeutics, Inc. has announced its Annual Meeting of Stockholders will be held on June 2, 2026, to elect directors and ratify auditors.

Tenax Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on several key proposals, including the election of directors and approval of amendments to the company's certificate of incorporation.

Tenax Therapeutics is holding its annual meeting on June 11, 2025, to vote on director elections, officer exculpation, stockholder action requirements, executive compensation, and auditor ratification.

Tenax Therapeutics is asking stockholders to approve an amendment to its 2022 Stock Incentive Plan to increase the number of shares authorized for issuance by 7,935,912 shares.

Tenax Therapeutics has hired Morrow Sodali to assist with proxy solicitation for its upcoming annual meeting on June 7, 2024.

Tenax Therapeutics has filed a definitive proxy statement with the SEC.

Tenax Therapeutics files an amendment to its S-1 registration statement related to a proposed public offering of common stock, warrants, and pre-funded warrants.

Tenax Therapeutics aims to raise up to $12 million through a public offering of common stock, warrants, and pre-funded warrants to advance its oral levosimendan (TNX-103) Phase 3 trial for pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF).

Christopher Thomas Giordano has filed an amendment to Schedule 13D, indicating an exit from his beneficial ownership of Tenax Therapeutics common stock.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported a 3.3% stake in Tenax Therapeutics, Inc.

T. Rowe Price Associates, Inc. filed an amendment to its Schedule 13G, reporting a beneficial ownership of 2.2% in Tenax Therapeutics, Inc.

Millennium Management LLC and Israel A. Englander have reported a 5.1% beneficial ownership stake in Tenax Therapeutics, Inc.

Logos Global Management LP and affiliated entities have filed a Schedule 13G reporting a 3% beneficial ownership stake in Tenax Therapeutics, Inc.

Stonepine Capital Management, LLC and associated entities have filed a Schedule 13G reporting a 3.7% beneficial ownership stake in Tenax Therapeutics, Inc.

Venrock Healthcare Capital Partners and affiliates have reported a 9.9% beneficial ownership stake in Tenax Therapeutics, Inc. as of March 31, 2026.